When a Study Cast Doubt on a Heart Pill, the Drug Company Turned to Tom Price
By Robert Faturechi,
ProPublica
| 01. 19. 2017
After hearing from a company whose CEO was a campaign contributor, a congressional aide to Donald Trump’s HHS nominee repeatedly pushed a federal health agency to remove a critical drug study from its website.
The $3 pill known as BiDil was already a difficult sell when a Georgia-based pharmaceutical company bought the marketing rights a few years ago. A treatment for African Americans suffering from heart failure, BiDil had never really caught on, forcing the drug company that developed it to take a buyout offer. One strike against the drug was a 2009 study that raised questions about its safety and effectiveness.
So last summer, the new owner of the drug, Arbor Pharmaceuticals LLC of Atlanta, sought to get the study taken down from a government website. For help, the company turned to the office of a congressman to whom the CEO had given the maximum $2,700 campaign donation — Rep. Tom Price, the Georgia Republican nominated by Donald Trump to become head of the Department of Health and Human Services.
Over the next few months, one of Price’s aides...
Related Articles
By Miranda Bryant, The Guardian | 08.27.2025
Denmark’s prime minister, Mette Frederiksen, has apologised for the first time for the forced contraception scandal in which thousands of Greenlandic girls and women were fitted with contraceptive coils without their permission or knowledge.
Describing it as “systemic discrimination” against...
By Carter Sherman, The Guardian | 08.23.2025
For Erica L and her husband, in-vitro fertilization was the “nuclear option”.
After two years of trying to conceive, Erica and her husband had no idea why they could not have a baby. Doctors said only that they had “unexplained...
By Annika Inampudi, Science | 08.01.2025
In June, Sara* received a message asking whether she wanted to continue to participate in a massive, multicenter research project led by scientists at Aarhus University in Denmark. The iPsych study, the message said, had sequenced her genetic data from...
By Riley Beggin and Jeff Stein, The Washington Post | 08.03.2025
The White House does not plan to require health insurers to provide coverage for in vitro fertilization services, two people with knowledge of internal discussions said, even though the idea was one of President Donald Trump’s key campaign pledges.
Last...
